LeMaitre Vascular, Inc. (LMAT) Stock

LeMaitre Vascular, Inc. (LMAT) is a Healthcare stock trading at $93.95 (as of 2026-06-18), with a market capitalization of $2.16B and a trailing P/E of 34.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for treating peripheral vascular disease. Its product categories include vascular catheters (such as viewing, removal, occlusion, and perfusion types) and accessories and implants used in procedures such as carotid endarterectomy and vascular bypass.

Valuation — source: SEC EDGAR (first-party)
Price$93.95
Market Cap$2.16B
P/E Ratio34.8
EV / EBITDA25.6
Price / Book5.32
Price / Sales8.44
Dividend Yield0.9%
DCF Value (model)$83.73
DCF Upside vs Price-10.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$249.60M
Net Margin23.1%
Return on Equity15.3%
Current Ratio14.32
Revenue Growth (YoY)13.5%
EPS Growth (YoY)30.1%
FCF Growth (YoY)100.4%
Financial Health — source: SEC EDGAR
Altman Z-Score7.81 (safe)
Valuation vs Sector & Industry
Stock P/E34.8
Sector P/E (Healthcare)21.0
Industry P/E (Medical Equipment)31.7
vs Sector66.0%
vs Industry9.6%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($343.25M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOGeorge W. LeMaitre
Employees651
CountryUS
IPO Date2006-10-19

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Artivion, Inc. (AORT)
  • Establishment Labs Holdings Inc. (ESTA)
  • National Vision Holdings, Inc. (EYE)
  • AtriCure, Inc. (ATRC)
  • PROCEPT BioRobotics Corporation (PRCT)
  • Cadre Holdings, Inc. (CDRE)
  • AxoGen, Inc. (AXGN)
  • Enovis Corporation (ENOV)
LMAT earnings history · LMAT institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.